ERJ open research
THE BEST IN OPEN ACCESS BASIC, TRANSLATIONAL & CLINICAL RESPIRATORY RESEARCH

Early View

Original article

# Depressive symptoms among patients with chronic obstructive pulmonary disease according to smoking status – a Danish nationwide case-control study of 21184 patients

Jakob Hedemark Vestergaard, Pradeesh Sivapalan, Rikke Sørensen, Josefin Eklöf, Imane Achir Alispahic, Anna von Bülow, Niels Seersholm, Jens-Ulrik Stæhr Jensen

Please cite this article as: Vestergaard JH, Sivapalan P, Sørensen R, *et al*. Depressive symptoms among patients with chronic obstructive pulmonary disease according to smoking status – a Danish nationwide case-control study of 21184 patients. *ERJ Open Res* 2020; in press (https://doi.org/10.1183/23120541.00036-2020).

# Depressive symptoms among patients with chronic obstructive pulmonary disease according to smoking status – a Danish nationwide case-control study of 21 184 patients

Jakob Hedemark Vestergaard[1], Pradeesh Sivapalan [1, 2], Rikke Sørensen [3], Josefin Eklöf [1], Imane Achir Alispahic[1], Anna von Bülow[1], Niels Seersholm[1], Jens-Ulrik Stæhr Jensen[1,4]

[1]Department of Internal Medicine, Respiratory Medicine Section, Herlev and Gentofte Hospital, University Hospital of Copenhagen, Denmark

[2]Department of Internal Medicine, Zealand University Hospital, Roskilde, Denmark

[3]Department of Cardiology, Rigshospitalet, University Hospital of Copenhagen, University of Copenhagen, Denmark

[4]PERSIMUNE, Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark

**Corresponding author**

Jakob Hedemark Vestergaard MD,

Department of Internal Medicine, Respiratory Medicine Section,

Herlev and Gentofte Hospital, University Hospital of Copenhagen,

Kildegaardsvej 28, 2900 Hellerup, Denmark

**Key words**

COPD, smoking cessation, depression, mortality

## ABSTRACT

**Introduction:** Depressive symptoms appear more often among patients with chronic obstructive pulmonary disease (COPD) and are associated with reduced disease control and increased mortality. Both smoking and COPD increase the risk of depressive symptoms. Whether smoking cessation among COPD patients affects the occurrence of depressive symptoms is unknown. We

**SUPPLEMENTARY**

**Table 1** Prescription antidepressants collected at any community or hospital-based outpatient pharmacy during the study period.

| Smoking status | Smokers | Ex-smokers |
|---|---|---|
| Redeemed prescriptions for any antidepressant, n (%) | | |
| >=1 | 2,011 (19.0) | 1,821 (17.2) |
| >=2 | 1,564 (14.8) | 1,464 (13.8) |
| Time to first collected prescription for any antidepressant, days, median (IQR) | 44 (15-116) | 56 (18-204) |
| Study days, median (IQR) | 154 (0-561) | 296 (7-1008) |

*IQR* Interquartal range

**Table 2** Admission to a psychiatric hospital with either depression, anxiety or bipolar disorder during the study period.

| Smoking status | Smokers | Ex-smokers |
|---|---|---|
| Admission with either depression, anxiety or bipolar disorder, n (%) | 157 (1.5) | 114 (1.1) |
| Admission diagnoses, n (%) | | |
| Depression | 97 (61.8) | 66 (57.9) |
| Anxiety | 42 (26.8) | 51 (44.7) |
| Bipolar disorder | 41 (26.1) | 16 (14.0) |
| Days to first admission with either depression, anxiety or bipolar disorder | 239 (99-587) | 484 (177-1086) |

*WHO-DDD* World Health Organization Define Daily Dose; *IQR* Interquartal range

**Table 3** Hospital-requiring acute COPD exacerbations during the study period according to smoking status and collection of prescription antidepressants.

| Smoking status | Smokers | Ex-smokers |
|---|---|---|
| Hospital-requiring acute COPD exacerbations pr. 1000 study days | 2.3 | 1.5 |
| Any precription antidepressants* | 2.2 | 1.5 |
| No prescription antidepressants** | 2.5 | 1.6 |

*Patients who collected any amount of prescription antidepressants during the study period.

** Patients who collected no prescription antidepressants during the study period.

*COPD* Chronic obstructive pulmonary disease;

hypothesized that smoking cessation in patients with COPD leads to reduced use of antidepressants and fewer admissions to psychiatric hospitals with depression, anxiety or bipolar disorder.

**Methods:** We conducted a nationwide retrospective case-control study, in patients from The Danish Register for Chronic Obstructive Pulmonary Disease (DrCOPD) with spirometry verified COPD, age ≥40 years, a history of smoking and absence of cancer. Consistent smokers were matched 1:1 with ex-smokers using a propensity score model. Prescription fillings of antidepressants and risk of admissions to psychiatric hospitals with either depression, anxiety or bipolar disorder both descriptively was assessed by Cox proportional hazard models.

**Results:** We included 21,184 patients. A total of n=2,011 consistent smokers collected antidepressant prescriptions compared with 1,821 ex-smokers. Consistent smoking was associated with increased risk of filling prescription on antidepressants (HR 1.4, 95% CI 1.3-1.5, p<0.0001). and with increased risk of psychiatric hospital admission with either depression, anxiety or bipolar disorder (HR 2.0, 95% CI 1.6-2.5). The associations persisted after adjustment for former use of antidepressants.

**Conclusion:** Consistent smoking among COPD patients was associated with increased use of antidepressants and admissions to psychiatric hospitals with either depression, anxiety or bipolar disorder, compared to smoking cessation.

## INTRODUCTION

Chronic obstructive pulmonary disease (COPD) is responsible for an increasing number of deaths worldwide, and COPD is expected to be the third-largest cause of death in the world by 2030[1]. Smoking is well established as the main risk factor for developing COPD[2].

Depressive symptoms are more frequent among patients with COPD[3]. Depressive patients with COPD have an increased frequency of exacerbations [4, 5], less effective pulmonary rehabilitation, impaired quality of life, aggravated dyspnea[6] and increased mortality[7, 8]. Separately, both smoking and COPD are associated with increased risk of depressive symptoms[2, 9-11].

Several studies conducted in the general population have investigated the effect of smoking cessation on both development of depressive symptoms and the effect on existing depressive symptoms. In studies on a multinational cohort of smokers, who were randomly selected from the general population, smoking cessation tended to decrease the occurrence of depressive symptoms[12], and among those with no prior depressive symptoms smoking cessation did not increase risk of depressive symptoms[13]. Moreover, in large cross-sectional studies, ex-smokers were less likely to have depression[14] or comorbid depression/anxiety[15] than did active smokers. Further, continued smoking may be associated with guilt and shame and may thus lead to depression[16]

However, all the above-mentioned studies were performed in highly selected patients, and a possible history of COPD was not considered. Whether smoking cessation in COPD patients affects the occurrence of depressive symptoms is unknown and has to our knowledge not previously been described.

The hypothesis in the current study is that COPD patients who stop smoking have a reduced occurrence of depressive symptoms, both measured as use of antidepressant medication and as admissions to psychiatric hospitals with mental depression, bipolar disorder or anxiety.

## METHODS

We conducted a nationwide retrospective case-control study in outpatients with COPD. As a proxy for depressive symptoms, we examined rates of collection of prescription antidepressants and rates of hospitalization due to either depression, anxiety or bipolar disorder.

### Data

Data were obtained from the following Danish registers

(1) The Danish Register for Chronic Obstructive Pulmonary Disease (DrCOPD). A nationwide register including outpatients with COPD and inpatients admitted with acute exacerbation of COPD since 1st of January 2010. The COPD diagnoses were specialist-verified and with spirometry with a Tiffeneau-Pinelli index less than 0.7 All Danish hospitals treating COPD reports to DrCOPD, and data consistency and completeness is monitored yearly [17, 18].

Main variables recorded are forced expiratory volume in 1 second (FEV1), body mass index (BMI), Medical Research Council Dyspnea Scale (MRC), smoking status, treatment with long-acting beta-adrenocepter agonist (LABA) or long-acting muscarinic receptor antagonist (LAMA) and treatment with inhaled corticosteroids. Information on survival is provided from the Danish Civil Registration System [18].

(2) The Danish National Patient Registry (DNPR). A nationwide register containing information on all contacts with the public Danish health service, including hospital admissions and visits to outpatient clinics. Every contact contains a physician coded primary diagnosis and one or more secondary diagnoses, all according to ICD (International Classification of Diseases), $10^{th}$ revision (ICD-10) since 1994. DNPR receive information from both somatic and psychiatric sectors [19].

(3) Danish National Health Service Prescription Database (DNHSPD). A nationwide register comprising information on all redeemed prescription medicine since 2004. Data from all Danish community pharmacies and hospital-based outpatient pharmacies are reported to DNHSPD. For every redeemed medication follows information on strength, dose, ATC (Anatomical Therapeutic Chemical classification) code and product name [20].

**Study population**

We identified COPD outpatients from DrCOPD, with a visit between 1st of January 2010 and 31st of October 2017. Inclusion criteria were age ≥40 years and a history of smoking. We excluded patients diagnosed with cancer, apart from basal cell carcinoma of the skin, in DNPR within ten years prior to study entry.

The observation period for each patient was defined as the time between the first outpatient visit with registered smoking status (inclusion date) and the registered end date of observation or the time of death. In case there was no registered end of observation, the end date was defined as 31th of October 2017. In case of missing smoking status at any visit, the last observation was carried forward.

Based on data from the entire observation period, patients were divided into consistent-smokers and ex-smokers. Ex-smokers were defined by consistent registration of smoking status as former smoker during the study period. Patients observed with an in-consistent smoking status were excluded. We defined inconsistent smoking as registration of smoking status as both active and former during the study period.

Propensity matching was performed using Greedy matching algorithm[21] to match consistent smokers 1:1 with ex-smokers. We estimated a propensity score conditional on gender, age, BMI,

FEV1, MRC) and major comorbidities (cerebrovascular disease, heart failure, diabetes mellitus, chronic kidney failure, acute myocardial infarction, peripheral artery disease, atrial fibrillation and arterial hypertension) with smoking as the dependent variable. All further analyses were performed on the propensity matched population.

Data from DNPR was used to characterize co-morbidities and to estimate the number of exacerbations of COPD prior to inclusion and in the study period. Co-morbidities included were cerebrovascular disease, heart failure, diabetes mellitus, chronic kidney failure, acute myocardial infarction, peripheral artery disease, atrial fibrillation and arterial hypertension.

The study was approved by the Danish Data Protection Agency (journal no.: VD-2018-264, I-Suite 6504). The study protocol was published online at www.coptrin.dk before statistical analyses were performed.

**Outcomes**

The primary outcome was collection of prescription antidepressants (ATC codes N06AA01-N06AX26 except N06AAX12). The primary endpoint was investigated separately and combined with all-cause mortality treated as a competing risk. The secondary outcome was admission to a psychiatric hospital with either depression, anxiety or bipolar disorder (ICD-10 codes DF31-34 and DF40-41). Collection of prescription antidepressants was identified in DNHSPD, and admissions with either depression, anxiety or bipolar disorder were identified in DNPR. The mortality date was drawn from DrCOPD.

**Statistical analysis**

All analyses were performed on a propensity matched population of consistent smokers and ex-smokers.

For descriptive statistics we estimated median values and interquartile ranges for continuous variables and frequencies and proportions for categorical variables.

Use of prescription antidepressants was quantified by rates of World Health Organization Defined Daily Doses (WHO-DDD) per 1,000 observation days. Rates of used WHO-DDD pr. 1,000 were calculated for all antidepressants cumulated (Table 2) and of major antidepressant drug groups (Table 3)

COX proportional hazard regressions were performed to estimate the risk of collection of prescription antidepressant or all-cause mortality. We performed competing risk analyses to further investigate all-cause mortality as a competing event to the collection of prescription antidepressant (Table 5). The above-mentioned Cox model was fitted with both Fine and Gray analyses of subdistribution hazard and with cause-specific analyses of the combined primary endpoint by mutual censoring of endpoint elements. Finally, a Cox analysis was made to estimate the risk of admission to a psychiatric hospital due to either depression, anxiety or bipolar disorder (Table 6).

Sensitivity analyses were performed by repeating the above-mentioned Cox-analyses extended with a stratification based on collection of either "no" or "any prescription" of antidepressants five years prior to study entry.

Results were presented as hazard ratios (HRs) with 95% confidence intervals (CI) and as subdistribution hazards (SR) with 95% CI.

To predict the cumulated incidence functions the Fine-Gray model was fitted to evaluate the risk of collection of prescription antidepressant and the risk of psychiatric hospital admissions due to either depression, anxiety or bipolar disorder.

Statistical analyses were performed using SAS statistical software 9.4 (SAS Institute Inc., Cary, NC, USA)

## RESULTS

We identified 57,843 outpatients with COPD during 1st of January 2010 and 31st of October 2017 and among those we identified 36,560 eligible patients comprising of 12,626 (34.5%) consistent smokers and 23,934 (65,5%) ex-smokers. In total, 10,592 consistent smokers and 10,592 ex-smokers were matched by propensity score (Figure 1). The c-statistics of the logistic regression model used for calculation of the propensity score was 0.69. Baseline characteristics of the propensity matched population are presented in Table 1. The two groups were overall similar, although there was a trend towards more ex-smokers than consistent smokers being treated with inhaled corticosteroids and LABA or LAMA.

### Use of antidepressants and admissions to psychiatric hospitals

The use of prescription antidepressants and psychiatric hospital admissions among consistent smokers and ex-smokers is shown in Table 2. Ex-smokers collected 30.4% fewer prescription antidepressants than consistent smokers measured as WHO-DDD pr. 1,000 study days. Additionally, ex-smokers collected less prescription antidepressant of any drug class. Further details are described in Supplementary Table 1.

The rates of psychiatric hospital admissions pr. 100,000 study days for ex-smokers and consistent smokers were 1.8 and 3.7 respectively. The main part of admissions in both groups were due to depression and more ex-smokers than consistent smokers were admitted with anxiety (Supplementary Table 2).

The rates of hospital-requiring acute COPD exacerbations pr. 1,000 study days for ex-smokers and consistent smokers were 1.5 and 2.3 respectively. Patients who collected any amount of prescription antidepressants during the study period did not have a higher exacerbation frequency (Supplementary Table 3).

**Outcome analyses**

The risk of use of any prescription antidepressant and all-cause mortality and the risk of admission to a psychiatric hospital with either depression, anxiety or bipolar disorder is presented for consistent smokers vs. ex-smokers is shown in Table 3. Smoking was associated with a significantly increased risk of collection of any prescription antidepressant or all-cause mortality (HR 1.6, 95% CI 1.5-1.6, p<0.0001) and in cause-specific analyses consistent smoking was also associated with an increased risk of use of prescription antidepressant alone (HR 1.4, 95% CI 1.3-1.5, p<0.0001), ex-smoking as reference

In competing event analysis using the Fine-Gray Method, smoking was associated with significantly increased subdistribution hazard of collection of any antidepressant prescription (sHR 1.3, 95% CI 1.2-1.3, p<0,0001) with a cumulative incidence function showing a constantly increased risk of smoking over time (figure 2).

The risk of admission to a psychiatric hospital with either depression, anxiety or bipolar disorder was larger for consistent smokers vs ex-smokers (HR 2.0, CI 1.6-2.5, p<0,0001) as presented in table 3. This result was largely unchanged in the competing event analyses with all-cause mortality using the Fine and Gray Model (sHR 1.6, 95% CI 1.3-2.0, p=0.0002) with a cumulative incidence function showing a constantly increased risk of smoking over time (figure 3).

**Sensitivity analyses**

We performed stratification of the propensity matched population based on either no use or any use of prescription antidepressants five years prior to baseline and subsequently repeated the main analyses with this stratification. Although weakened a little in strength, the signal was largely unchanged that consistent smoking was associated with an increased risk of both use of prescription antidepressants or all-cause mortality (HR 1.4, 95% CI 1.3-1.5, p<0,0001), use of prescription antidepressants alone (HR 1.1, 95% CI 1.01-1.14, p=0.03) and admission to a psychiatric hospital with either depression, anxiety or bipolar disorder (HR 1.6, 95% CI 1.57-1.73, p<0.0001).

## DISCUSSION

In this study, we found a strong and substantial association between consistent smoking among COPD patients and the use of antidepressants as well as admission to a psychiatric hospital with either depression, anxiety or a bipolar disorder. All analyses were made on a cancer-free, propensity matched population of consistent smokers and ex-smokers, and the significant associations persisted even after adjustment for former use of antidepressants.

Consistent smoking was associated with a 57% increased risk of prescription of antidepressants or all-cause mortality and a 38% increased risk of prescription of antidepressants alone. The latter might even underestimate the association since death was a frequent event in this population, and as expected, was more frequent among consistent smokers. A majority of both consistent smokers and ex-smokers had moderate to severe COPD based on spirometry, and approximately half of patients had one or more exacerbations of COPD in the past year at baseline.

We found an almost two-fold increased risk of admission to a psychiatric hospital with either depression, anxiety or bipolar disorder in patients with consistent smoking compared to ex-smokers with approximately same tobacco exposure and lung function.

One might suspect depressive COPD patients of being less likely to cease smoking due to anhedonia and therefore overrepresented among consistent smokers. Therefore, we conducted sensitivity analyses with stratification by use of antidepressants five years prior to inclusion in the study to account for this: the signal was largely unchanged.

It is well established that people with mental disorders are more likely to smoke than those without mental disorder with reported rates two to four times higher. Despite increased smoking rates, people with mental disorders respond well to standard smoking cessation strategies[22], and cessation rates are equal to the general population[23].

If smoking cessation does reduce the incidence of mental depression among COPD patients, what might be the mechanism? Both smoking and depression are related to altered dopamine function, and the associations we found might in part be explained by normalization of dopamine circuits, when a person permanently stops smoking. Depression is, apart from dysfunctional serotonin and norepinephrine circuits, associated with dopamine dysfunction and depressive patients have significantly lower dopamine transporter binding secondary to lower dopamine levels[24]. Smoking a cigarette leads to a rapid increase in plasma nicotine with subsequent binding to nicotinic cholinergic receptors in the brain, though persistent exposure to nicotine leads to desensitisation of nicotinic cholinergic receptors and development of tolerance to nicotine[25]. Importantly, a study using FDOPA PET-scan showed a lower dopamine synthesis capacity among smokers that normalised after three-month smoking abstinence[26].

**Strengths and limitations**

To our knowledge, this is the first large study among COPD patients investigating the association between consistent smoking or consistent smoking abstinence and the risk of depression markers. The study was conducted on a large, well defined, nationwide cohort of COPD patients with complete data available on prescription of medication and hospital admissions[17-20].

Despite these strengths, some limitations of the study should be considered: First, we only included patients who were consistent smokers or consistent ex-smokers during the study period. It would have been of great interest to analyse the use of antidepressants and admissions to psychiatric hospitals before and immediately after smoking cessation. However, we judged it necessary to exclude these patients since less than 10% of the observation time was after smoking cessation. We suspected a part of this skewness to be caused by patients not being able physically to smoke during the last months of their life, which is hardly representative for the hypothesis tested. Second, although we did attempt to adjust and match for all known and possible confounders, residual confounding may very well be present and drive a part of the signal observed. This is an inert weakness of the design. However, we did try to address this by performing different analyses, and also by repeating all analyses after stratifying for previous use of antidepressants. Additionally, an interventional design is not possible for ethical reasons.

Third, although our databases are complete regarding most data, some variables were missing in some patients. A small minority of patients had missing data on smoking status. This could not be handled by imputation, since it was the main investigated risk variable. Nevertheless, patients with missing data on this or other variables may very well be a special group regarding the explored outcomes. Fourth, we did not have enough data and observation time on COPD patients who

succeeded in smoking cessation, especially after cessation. Having such data would have qualified the conclusions further – this could be the scope of a future study on this important subject.

## CONCLUSION

Consistent smoking among COPD patients is associated with an increased risk of using antidepressants and an increased risk of hospital admissions related to depression, anxiety or bipolar disorder. Possible explanations include an actual effect via the cerebral nicotine receptors and the influence on the dopamine system, or that smoking cessation merely is more likely among non-depressed, although the latter is somewhat contradicted by studies estimating the chance of smoking cessation in patients with and without psychiatric illnesses, and our results where stratified for previous use of antidepressants. Smoking COPD patients should always be encouraged to stop for several reasons; our study indicates that improving existing mood disorders and reducing the risk of novel mood disorders may be important reasons.


## Acknowledgements

We thank the Danish Register for Chronic Obstructive Pulmonary Disease, Danish National Patient Registry and Danish National Health Service Prescription Database for allowing us data for this study.

## Funding

This study was funded by the Department of Internal Medicine, Herlev and Gentofte Hospital, University Hospital of Copenhagen, Denmark.

**Conflict of interest**

All authors declare no conflict of interest.

**Abbreviations**

AMI: Acute myocardial infarction

ATC: Anatomical Therapeutic Chemical

BMI: Body mass index

CI: Confidence interval

CKF: Chronic Kidney Failure

COPD: Chronic obstructive pulmonary disease

CVD: Cerebrovascular disease

DM: Diabetes mellitus

DNHSPD: Danish National Health Service Prescription Database

DNPR: Danish National Patient Registry

DrCOPD: Danish Register for Chronic Obstructive Pulmonary Disease

FEV1: Forced expiratory volume within 1 second

HF: Heart failure

HR: Adjusted hazard ratio

ICD: International Classification of Diseases

IQR: Interquartile range

LABA: Long-acting beta-adrenocepter agonist

LAMA: Long-acting muscarinic receptor antagonist

MRC: Medical Research Council Dyspnea Scale

NaSSA: Noradrenergic and specific serotonergic antidepressant

PAD: Peripheral artery disease

sHR: Subdistribution hazard ratio

SNRI: Serotonin-norepinephrine reuptake inhibitor

SSRI: Selective serotonin reuptake inhibitor

TCA: Tricyclic antidepressant

WHO-DDD: World Health Organization Defined Daily Dose

## References


1. http://www.who.int/respiratory/copd.
2. Goodwin, R.D., et al., *Depression, Anxiety, and COPD: The Unexamined Role of Nicotine Dependence.* Nicotine & Tobacco Research, 2012. **14**(2): p. 176-183.
3. Matte, D.L., et al., *Prevalence of depression in COPD: A systematic review and meta-analysis of controlled studies.* Respiratory Medicine, 2016. **117**: p. 154-161.
4. Papaioannou, A.I., et al., *The impact of depressive symptoms on recovery and outcome of hospitalised COPD exacerbations.* European Respiratory Journal, 2013. **41**(4): p. 815-823.
5. Iyer, A.S., et al., *Depression Is Associated with Readmission for Acute Exacerbation of Chronic Obstructive Pulmonary Disease.* Annals of the American Thoracic Society, 2016. **13**(2): p. 197-203.
6. von Leupoldt, A., et al., *The Impact of Anxiety and Depression on Outcomes of Pulmonary Rehabilitation in Patients With COPD.* CHEST, 2011. **140**(3): p. 730-736.
7. de Voogd, J.N., et al., *Depressive Symptoms as Predictors of Mortality in Patients With COPD.* CHEST, 2009. **135**(3): p. 619-625.
8. Lou, P., et al., *Effects of Smoking, Depression, and Anxiety on Mortality in COPD Patients: A Prospective Study.* Respiratory Care, 2014. **59**(1): p. 54-61.
9. Ng, T.-P., et al., *Co-morbid association of depression and COPD: A population-based study.* Respiratory Medicine, 2009. **103**(6): p. 895-901.
10. Fluharty, M., et al., *The Association of Cigarette Smoking With Depression and Anxiety: A Systematic Review.* Nicotine & Tobacco Research, 2017. **19**(1): p. 3-13.
11. Luger, T.M., J. Suls, and M.W. Vander Weg, *How robust is the association between smoking and depression in adults? A meta-analysis using linear mixed-effects models.* Addictive Behaviors, 2014. **39**(10): p. 1418-1429.
12. Shahab, L., S. Andrew, and R. West, *Changes in prevalence of depression and anxiety following smoking cessation: results from an international cohort study (ATTEMPT).* Psychological Medicine, 2014. **44**(1): p. 127-141.
13. Bolam, B., R. West, and D. Gunnell, *Does Smoking Cessation Cause Depression and Anxiety? Findings from the ATTEMPT Cohort.* Nicotine & Tobacco Research, 2011. **13**(3): p. 209-214.
14. McClave, A.K., et al., *Associations between smoking cessation and anxiety and depression among U.S. adults.* Addictive Behaviors, 2009. **34**(6): p. 491-497.
15. Mykletun, A., et al., *Smoking in relation to anxiety and depression: Evidence from a large population survey: The HUNT study.* European Psychiatry, 2008. **23**(2): p. 77-84.
16. Dirkse, D., et al., *Shame, guilt, and communication in lung cancer patients and their partners.* Curr Oncol, 2014. **21**(5): p. e718-22.

17. Zhao, Q.M., et al., *Diagnostic Value of Serum Procalcitonin in Early Infection after Internal Fixation for Traumatic Fracture.* Clin Lab, 2017. **63**(11): p. 1827-1830.
18. Lange, P., et al., *Danish Register of chronic obstructive pulmonary disease.* Clinical epidemiology, 2016. **8**: p. 673-678.
19. Schmidt, M., et al., *The Danish National Patient Registry: a review of content, data quality, and research potential.* Clinical epidemiology, 2015. **7**: p. 449-490.
20. Johannesdottir, S.A., et al., *Existing data sources for clinical epidemiology: The Danish National Database of Reimbursed Prescriptions.* Clinical epidemiology, 2012. **4**: p. 303-313.
21. Bergstralh EJ, K.J. *Computerized Matching of Cases to Controls.* *https://www.mayo.edu/research/documents/biostat-56pdf/doc-10026923*. 1995.
22. Tidey, J.W. and M.E. Miller, *Smoking cessation and reduction in people with chronic mental illness.* BMJ : British Medical Journal, 2015. **351**: p. h4065.
23. Banham, L. and S. Gilbody, *Smoking cessation in severe mental illness: what works?* Addiction, 2010. **105**(7): p. 1176-1189.
24. Belujon, P. and A.A. Grace, *Dopamine System Dysregulation in Major Depressive Disorders.* The international journal of neuropsychopharmacology, 2017. **20**(12): p. 1036-1046.
25. Benowitz, N.L., *Nicotine Addiction.* New England Journal of Medicine, 2010. **362**(24): p. 2295-2303.
26. Rademacher, L., et al., *Effects of Smoking Cessation on Presynaptic Dopamine Function of Addicted Male Smokers.* Biological Psychiatry, 2016. **80**(3): p. 198-206.

**Table 1** Baseline characteristics of propensity matched COPD outpatients during 1stth of January 2010 and 31st of October 2017.

| Smoking status | Smoker n=10,592 | Ex-smoker n=10,592 |
|---|---|---|
| Demographics | | |
| Women | 5,363 (50.3) | 5,490 (50.6) |
| Age, median (IQR) | 66.9 (59.9-74.3) | 67.6 (60.2-74.7) |
| BMI, median (IQR) | 24.0 (21-29) | 24.7 (21.9-29.0) |
| BMI | | |
| <18,5 | 824 (7.8) | 670 (6.3) |
| 18,5-24,9 | 4,613 (43.6) | 4,682 (44.2) |
| 25-29,9 | 2,841 (26.8) | 3,090 (29.2) |
| 30-34,9 | 1,463 (13.8) | 1,391 (13.1) |
| >35 | 851 (8.0) | 759 (7.2) |
| MRC | | |
| 1 | 1,199 (11.3) | 1,327 (12.5) |
| 2 | 3,274 (30.9) | 3,275 (30.9) |
| 3 | 3,206 (30.3) | 3,112 (29.4) |
| 4 | 1,877 (17.7) | 1,829 (17.3) |
| 5 | 1,036 (9.8) | 1,049 (9.9) |
| FEV1 % predicted, median (IQR) | 50 (37-64) | 51 (37-65) |
| FEV1 % predicted | | |
| >80 | 739 (7.0) | 912 (8.6) |
| 50-79 | 4,765 (45.0) | 4,656 (44.0) |
| 30-49 | 3,779 (35.7) | 3,648 (34.4) |
| <30 | 1,309 (12.4) | 1,376 (13.0) |
| Exacerbations, the past year | | |
| 0 | 5,517 (52.1) | 5,544 (52.3) |
| 1 | 2,447 (23.1) | 2,410 (22.8) |
| >=2 | 2,628 (24.8) | 2,638 (24.9) |
| Inhaled LABA or LAMA | 8,151 (80.4) | 9,096 (85.9) |
| Inhaled corticosteroids | 6,957 (65.7) | 7,867 (74.3) |
| | | |
| Atrial fibrillation | 1,228 (11.6) | 1,174 (11.1) |
| Heart failure | 1,262 (11.9) | 1,204 (11.4) |
| Acute myocardial infarction | 723 (6.8) | 667 (6.3) |
| Hypertension | 2,875 (27.1) | 2,745 (25.9) |
| Diabetes mellitus | 1,141 (10.8) | 1,092 (10.3) |
| Cerebrovascular disease | 963 (9.1) | 888 (8.4) |
| Peripheral artery disease | 1,179 (11.1) | 1,195 (11.3) |
| Chronic renal failure | 391 (3.7) | 330 (3.1) |

Data are presented as %(n) when not otherwise specified. *BMI* Body mass index, *MRC* Medical Research Council Dyspnea Scale, *FEV1* Forced expiratory volume in 1 sec., *IQR* Interquartile range.

**Table 2** Prescription antidepressants collected at any community or hospital-based outpatient pharmacy and admissions to a psychiatric hospital with either depression, anxiety or bipolar disorder during the study period.

| Smoking status | Consistent smokers | Ex-smokers |
|---|---|---|
| WHO-DDD of antidepressants collected pr. 1,000 study days | | |
| Any antidepressants | 310.9 | 216.5 |
| TCA | 14.2 | 8.3 |
| SSRI | 186.7 | 137.4 |
| NaSSA | 49.1 | 38.5 |
| SNRI | 55.4 | 29.6 |
| Others | 3.1 | 1.6 |
| Admissions to psychiatric hospital under the diagnosis of depression, anxiety or bipolar disorder pr. 100,000 study days | 3.7 | 1.8 |

*WHO-DDD* World Health Organization Define Daily Dose; *IQR* Interquartile range; *TCA* Tricyclic antidepressants; SSRI Selective serotonin reuptake inhibitor; NaSSa Noradrenergic and specific serotonergic antidepressants; SNRI Serotonin–norepinephrine

**Table 3** Association between ongoing smoking and use of antidepressants or all-cause mortality and between ongoing smoking and risk of psychiatric hospital admission with either depression, anxiety or bipolar disorder

| | HR | 95% CI | p-value |
|---|---|---|---|
| Collection of any antidepressant or all-cause mortality* | 1.6 | 1.5-1.6 | <0.0001 |
| Collection of any antidepressant | 1.4 | 1.3-1.5 | <0.0001 |
| All-cause mortality | 1.8 | 1.7-1.9 | <0.0001 |
| Admission with either depression, anxiety or bipolar disorder** | 2.0 | 1.6-2.5 | <0.0001 |

*Hazard ratios (HR) for collection of any prescription antidepressant or all-cause mortality and cause-specific HR for collection of any prescription antidepressant and all-cause mortality respectively. All-cause mortality was defined as death of any cause with no prior collection of any prescription antidepressant. **Hazard ratios (HR) for admission to a psychiatric hospital with either depression, anxiety or bipolar disorder; *CI* confidence interval.


57,047 outpatients with COPD identified from the DrCOPD cohort during 1st of January 2010 and 31st of October 2017
395: Age <40 years
8,085: Cancer or CIS
2,184: No history of smoking
5,386: Missing smoking status
169: Missing or extreme data
4,268: Varying smoking status
36,560: Eligible patients for propensity matching (12,626 smokers and 23,934 ex-smokers)
10,592: Smokers
10,592: Ex-smokers


Cumulative incidence (%)
30
20
10
0
0
500
1,000
1,500
2,000
2,500
Follow-up (days)
Smokers
Ex-smokers


Cumulative incidence (%)
40
30
20
10
0
0
500
1,000
1,500
2,000
2,500
Follow-up (days)
Smokers
Ex-smokers